normal or nearly normal mri provides strong reassurance that a large, high-grade cancer was not missed (shukla-Dave, a. et al. BJU Int. 99, 786-793 [2007] ).
Does it make sense to treat prostate cancer focally, even if appropriate candidates can be identified? what is the advantage of focal ablation over active surveillance? neither patients nor their physicians are enthusiastic about watchful waiting, an option chosen by only 6% of men (Harlan, s. r. et al. J. Urol. 170, 1804 -1807 [2003 ). would ablating a small cancer reduce the risk of future progression and the need for radical therapy?
the technology needed to ablate small regions or sectors of the prostate harboring a known cancer is rapidly becoming available. Cryotherapy is already being used (unfortunately outside of formal clinical trials) and the preliminary data is encouraging, although the criteria for eligibility, the parameters of treatment, the length of follow-up, and the absence of patient-reported outcomes make these results hard to interpret.
ultrasound-guided high-intensity focused ultrasound (HiFu), photodynamic therapy using newly developed light-sensitizing agents, and mri-guided HiFu are all promising new tools that will place focal therapy easily within the grasp of the medical community.
in this issue of Nature Reviews Urology, imaging and biopsy techniques for improving the detection and character ization of tumors within the prostate are the subjects of a review by Baris turkbey et al. (page 191) and a news & views commentary by Gerald andriole (page 188). the issue of using focal therapy in patients with early-stage prostate cancer is examined by vladimir mouraviev and colleagues in their review (page 205). the authors discuss the stage migration observed in prostate cancer, and pathologic factors that are important in selecting potential candidates for focal therapy. this review, along with the other articles, highlights the importance of perfecting an image-guided technique and accurate characterization of tumors as being essential in the development of a focal therapy approach to the management of prostate cancer. now is the time to plan the clinical trials that are essential if we are to determine whether focal therapy makes any sense and is of real benefit to our patients. 
